PSA Kinetics Provide Improved Prediction of Survival in Metastatic Hormone-Refractory Prostate Cancer

Urology

Volumn 72, Issue 4, 2008, Pages 903-907

  Robinson, David ^a   Sandblom, Gabriel ^b   Johansson, Robert ^c   Garmo, Hans ^d   Aus, Gunnar ^e   Hedlund, Per Olov ^f   Varenhorst, Eberhard ^g  

^a RYHOV COUNTY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; FLUTAMIDE; HEMOGLOBIN; POLYESTRADIOL PHOSPHATE; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN;

AGE; AGED; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SOLOWAY SCORE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; FLUTAMIDE; HUMANS; KINETICS; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT FAILURE; TRIPTORELIN;

EID: 52949136987     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.05.026     Document Type: Article

References (19)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Aus G., Robinson D., Rosell J., et al. Survival in prostate carcinoma-Outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: Results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 103 (2005) 943-951
3. Collette L., de Reijke T.M., and Schroder F.H. Prostate specific antigen: A prognostic marker of survival in good prognosis metastatic prostate cancer?. (EORTC 30892). Eur Urol 44 (2003) 182-189
4. Glass T.R., Tangen C.M., Crawford E.D., et al. Metastatic carcinoma of the prostate: Identifying prognostic groups using recursive partitioning. J Urol 169 (2003) 164-169
5. Fossa S.D., Jacobsen A.B., Ginman C., et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: A randomized phase II study. Eur Urol 52 (2007) 1691-1698
6. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
7. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232-1237
8. D'Amico A.V., Chen M.H., Cox M.C., et al. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. Urology 66 (2005) 571-576
9. Smaletz O., Scher H.I., Small E.J., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 (2002) 3972-3982
10. Daskivich T.J., Regan M.M., and Oh W.K. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. Urology 70 (2007) 527-531
11. Oudard S., Banu E., Scotte F., et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 18 (2007) 1828-1833
12. Semeniuk R.C., Venner P.M., and North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 68 (2006) 565-569
13. Rozhansky F., Chen M.H., Cox M.C., et al. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 106 (2006) 63-67
14. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984-3990
15. Robinson D., Sandblom G., Johansson R., et al. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. J Urol 179 (2008) 117-123
16. Hedlund P.O., and Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: Effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 trial study. Urology 55 (2000) 328-333
17. Pencina M.J., D'Agostino R.B.S., D'Agostino R.B.J., et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27 (2008) 157-172
18. Hosmer D.W., and Lemeshow S. Applied Logistic Regression. 2nd ed. (2000), John Wiley & Sons, New York 160-164
19. Chun F.K., Karakiewicz P.I., Huland H., et al. Role of nomograms for prostate cancer in 2007. World J Urol 25 (2007) 131-142